For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or o ...

UROGEN CORPORATE PRESENTATION JEFFERIES HEALTHCARE CONFERENCE June 2, 2020 2 FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential market opportunity of Jelmyto in LG-UTUC; commercial plans for favorable market access and physician uptake following the Jelmyto launch; plans for the successful launch of Jelmyto; the timing for completion of commerci ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Kate Bechtold - Senior Director, Investor Relations Liz Barrett - President & Chief Executive Officer Mark Schoenberg - Chief Medical Officer Jeff Bova - Senior Vice President, Commercial Peter Pfreundschuh - Chief Financial Officer Conference Call Participants Derek Archila - Stifel Nicolaus Paul Choi - Goldman Sachs Matthew Kaplan - Ladenburg Thalmann Boris Peaker - Cowen Leland Gershell - Oppenhe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2019 Earnings Conference Call March 2, 2020 8:30 AM ET Company Participants Kate Bechtold - Senior Director, Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - Chief Financial Officer Jeff Bova - Senior Vice President, Commercial Conference Call Participants Derek Archila - Stifel Nicolaus Chris Howerton - Jefferies Paul Choi - Goldman Sachs Ram Selvaraju - H.C. Wainwright & Co. Matthew Kapla ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to ________________ Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact name of registrant as specified in its charter) Israel 98-1460746 (Sta ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2019 Earnings Conference Call November 12, 2019 8:30 AM ET Company Participants Catherine Bechtold - Senior Director of IR Elizabeth Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - CFO Stephen Mullennix - COO Jeff Bova - SVP, Commercial Conference Call Participants Turner Kufe - JPMorgan Ram Selvaraju - H. C. Wainwright Boris Peaker - Cowen Leland Gershell - Oppenheimer Operator Good morning, ladies and gentlemen, thank you for sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2019 Earnings Conference Call August 12, 2019 8:30 AM ET Company Participants Catherine Bechtold - Director of Corporate Communications & IR Elizabeth Barrett - President, CEO Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - CFO & Secretary Stephen Mullennix - Chief Operating Officer Jeff Bova - Senior Vice President of Commercial Conference Call Participants Paul Choi - Goldman Sachs Boris Peaker - Cowen Ram Selvaraju - H.C. Wainwright Chris Howerton - Jeffer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to ________________ Commission file number: 001-38079 (State or other juri ...